HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir

BACKGROUND&AIMS: Recent clinical trials of direct-acting-antiviral agents (DAAs) against hepatitis C virus (HCV) achieved >90% sustained-virological response (SVR) rates, suggesting that cure often took place before the end of treatment (EOT). We sought to evaluate retrospectively whether ear...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Hepatol
Autori principali: Dahari, Harel, Canini, Laetitia, Graw, Frederik, Uprichard, Susan L., Araújo, Evaldo S.A., Penaranda, Guillaume, Coquet, Emilie, Riso, Aurelie, Renou, Christophe, Bourliere, Marc, Cotler, Scott J., Halfon, Philippe
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5081285/
https://ncbi.nlm.nih.gov/pubmed/26907973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhep.2016.02.022
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi